Table 1.
Patient and tumor characteristics
| No. (%) | |
|---|---|
| Age (y), median [range] | 52 [26–74] |
| Female gender | 127 (100) |
| ECOG PS | |
| 0 | 104 (81.9) |
| 1 | 20 (15.7) |
| 2 | 3 (2.4) |
| BRCA mutation status | |
| Present | 6 (4.7) |
| Undetermined clinical significance mutation | 5 (3.9) |
| Unknown | 39 (30.7) |
| Negative | 77 (60.6) |
| Premenopausal | 43 (33.9) |
| Histologic subtype | |
| Ductal invasive carcinoma | 110 (86.6) |
| Apocrine carcinoma | 8 (6.3) |
| Metaplastic carcinoma | 4 (3.1) |
| Other | 5 (3.9) |
| Grade | |
| 1 | 8 (6.3) |
| 2 | 61 (48) |
| 3 | 57 (44.9) |
| Unknown | 1 (0.8) |
| Ki-67 | |
| ≥ 70% | 73 (57.5) |
| < 70% | 50 (39.4) |
| Unknown | 4 (3.1) |
| cT | |
| 0 | 2 (1.6) |
| 2 | 52 (41) |
| 3 | 61 (48) |
| 4 | 12 (9.4) |
| cN | |
| 0 | 51 (40.2) |
| 1 | 68 (53.5) |
| 2 | 8 (6.3) |
| Clinical stage | |
| IIA | 3 (2.4) |
| IIB | 31 (24.4) |
| IIIB | 62 (48.8) |
| IIIC | 31 (24.4) |
| Neutrophil/lymphocyte ratio | |
| ≥ 1.8 | 74 (58.3) |
| < 1.8 | 53 (41.7) |
| Platelet/lymphocyte ratio | |
| ≥ 0.1 × 103 | 59 (46.5) |
| < 0.1 × 103 | 68 (53.5) |
ECOG PS — Eastern Cooperative Oncology Group performance status; y — years; no. — number